Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study.
Lee B, Wong HL, Tacey M, Tie J, Wong R, Lee M, Nott L, Shapiro J, Jennens R, Turner N, Tran B, Ananda S, Yip D, Richardson G, Parente P, Lim L, Stefanou G, Burge M, Iddawela M, Power J, Gibbs P. Lee B, et al. Among authors: shapiro j. Asia Pac J Clin Oncol. 2017 Aug;13(4):314-321. doi: 10.1111/ajco.12639. Epub 2016 Nov 25. Asia Pac J Clin Oncol. 2017. PMID: 27885818
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group. Mittmann N, et al. J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7. J Natl Cancer Inst. 2009. PMID: 19666851
Current opinion on optimal treatment for colorectal cancer.
Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, Shapiro JD. Price TJ, et al. Among authors: shapiro jd. Expert Rev Anticancer Ther. 2013 May;13(5):597-611. doi: 10.1586/era.13.37. Expert Rev Anticancer Ther. 2013. PMID: 23617351 Review.
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan CJ. Siu LL, et al. Among authors: shapiro jd. J Clin Oncol. 2013 Jul 1;31(19):2477-84. doi: 10.1200/JCO.2012.46.0543. Epub 2013 May 20. J Clin Oncol. 2013. PMID: 23690424 Clinical Trial.
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. Karapetis CS, et al. Among authors: shapiro jd. Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218517 Clinical Trial.
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.
Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD. Price TJ, et al. Among authors: shapiro jd. Expert Rev Anticancer Ther. 2014 Dec;14(12):1477-93. doi: 10.1586/14737140.2014.949678. Epub 2014 Aug 20. Expert Rev Anticancer Ther. 2014. PMID: 25138900 Review.
Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.
Turner NH, Wong HL, Field K, Wong R, Shapiro J, Yip D, Nott L, Tie J, Kosmider S, Tran B, Desai J, McKendrick J, Zimet A, Richardson G, Iddawela M, Gibbs P. Turner NH, et al. Among authors: shapiro j. Asia Pac J Clin Oncol. 2015 Sep;11(3):262-71. doi: 10.1111/ajco.12355. Epub 2015 Apr 14. Asia Pac J Clin Oncol. 2015. PMID: 25871458
Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A, Wong HL, Sjoquist KM, Gibbs P, Field K, Tran B, Shapiro J, Mckendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Roohullah A, et al. Among authors: shapiro j. World J Gastroenterol. 2015 May 7;21(17):5352-8. doi: 10.3748/wjg.v21.i17.5352. World J Gastroenterol. 2015. PMID: 25954110 Free PMC article.
2,680 results